Enovis Corporation (NYSE: ENOV) announced the U.S. launch of CT-RevitL, a veterinary photobiomodulation (PBM) laser therapy system developed by its Companion Animal Health division, on July 13, 2026.

The system is designed to treat pain, tissue healing, inflammation, and post-operative recovery in animals. CT-RevitL includes a technology called COMPASS, which the company describes as an intelligent treatment guidance system intended to provide calibrated dosing and reduce variability across users.

Companion Animal Health, headquartered in Newark, Delaware, claims to be the U.S. market leader in veterinary therapeutic laser technology and states it has been operating in the segment for more than 15 years. The company says CT-RevitL is supported by more than 150 published studies on PBM therapy.

Terry Ross, Group President of Enovis' Prevention & Recovery business segment, said in a statement: "CT-RevitL represents the next chapter in our commitment to deliver practical, innovative, evidence-based veterinary care."

The product is available to veterinary practices across the United States, with international availability planned for later phases. The launch includes a clinical education program and support from Companion Animal Health veterinary specialists.